Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy

• Published in: Frontiers in oncology 2021-10, Vol.11, p.749496-749496
• Main Authors: Elbanna, May, Chowdhury, Nayela N, Rhome, Ryan, Fishel, Melissa L
• Format: Article
• Language: English
• Subjects: cancer; combination (combined) therapy; DNA damage; Oncology; radiation therapy; radiosenisitizing agent; targeted therapy
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2021.749496

In the era of precision medicine, radiation medicine is currently focused on the precise delivery of highly conformal radiation treatments. However, the tremendous developments in targeted therapy are yet to fulfill their full promise and arguably have the potential to dramatically enhance the radiation therapeutic ratio. The increased ability to molecularly profile tumors both at diagnosis and at relapse and the co-incident progress in the field of radiogenomics could potentially pave the way for a more personalized approach to radiation treatment in contrast to the current ''one size fits all'' paradigm. Few clinical trials to date have shown an improved clinical outcome when combining targeted agents with radiation therapy, however, most have failed to show benefit, which is arguably due to limited preclinical data. Several key molecular pathways could theoretically enhance therapeutic effect of radiation when rationally targeted either by directly enhancing tumor cell kill or indirectly through the abscopal effect of radiation when combined with novel immunotherapies. The timing of combining molecular targeted therapy with radiation is also important to determine and could greatly affect the outcome depending on which pathway is being inhibited.